COVID-19

Repeated COVID-19 mRNA-based Vaccination Contributes to SARS-CoV-2 Neutralizing Antibody Responses in the Mucosa |
SARS-CoV-2 XBB.1.5 mRNA Booster Vaccination Elicits Limited Mucosal Immunity | Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022 | Nirmatrelvir Plus Ritonavir Reduces COVID-19 Hospitalization and Prevents Long COVID in Adult Outpatients |
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo – The ACTIV-6 Randomized Clinical Trial | Clinical and Functional Assessment of SARS-CoV-2 Sequelae among Young Marines – A Panel Study

The Risk of SARS-CoV-2 Transmission in Community Indoor Settings |
Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents |
Viral and Symptom Rebound Following Anti-SARS-CoV-2 Monoclonal Antibody Therapy in a Randomized Placebo-controlled Trial |
The Importance of Including Long COVID Outcomes When Developing Novel Treatments for Acute COVID-19 | The Persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 Infection

Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries |
Remdesivir-associated Survival Outcomes among Immunocompromised Patients Hospitalized for COVID-19 |
Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients |
Measurement of Circulating Viral Antigens Post-SARS-CoV-2 Infection in a Multicohort Study | Driving Under the Cognitive Influence of COVID-19 | Long COVID Facts and Findings

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO) |
COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type | Quantitative Susceptibility Mapping at 7 T in COVID-19: Brainstem Effects and Outcome Associations

Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection |
SARS-CoV-2-specific Plasma Cells are Not Durably Established in the Bone Marrow Long-lived Compartment after mRNA Vaccination |
Effects of Losartan on Patients Hospitalized for Acute COVID-19 |
Mechanisms of Long COVID and the Path Toward Therapeutics |
Post-hospitalization COVID-19 Cognitive Deficits

Genetic Tracing of Market Wildlife and Viruses at the Epicenter of the COVID-19 Pandemic |
Lower Mortality Risk Associated with Remdesivir + Dexamethasone versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19 |
Changes in Memory and Cognition During the SARS-CoV-2 Human Challenge Study

Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023 | Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024

Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates | Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials | Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial |
Effectiveness of COVID-19 Vaccines to Prevent Long COVID: Data from Norway |
Fibrin Drives Thromboinflammation and Neuropathology in COVID-19 |
Post-Acute Sequelae of COVID (PASC or Long COVID): An Evidenced-based Approach

Effectiveness of Historical Smallpox Vaccination against Mpox Clade II in Men in Denmark, France, the Netherlands and Spain, 2022 |
Pemivibart is Less Active against Recent SARS-CoV-2 JN.1 Sublineages | U.S. Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients |
COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People | Post-acute COVID-19 Outcomes Including Participant-reported Long COVID: Amubarvimab/romlusevimab versus Placebo in the ACTIV-2 Trial